U.S., Feb. 4 -- ClinicalTrials.gov registry received information related to the study (NCT06805825) titled 'A Study of the C-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced And/or Metastatic Solid Tumors Known to Express C-Kit' on Jan. 08.
Brief Summary: This open-label clinical trial will evaluate the safety and tolerability of NN3201 in subjects with advanced and/or metastatic solid tumors known to express c-Kit.
Study Start Date: Feb. 28
Study Type: INTERVENTIONAL
Condition:
Gastrointestinal Stromal Tumors
Small-cell Lung Cancer
Adenoid Cystic Carcinoma
Uveal Melanoma
Neuroendocrine Tumors
Chromophobe Renal Cell Carcinoma
Clear Cell Renal Cell Carcinoma
Intervention:
DRUG: NN3201
A c-Kit targeting fully human monoclonal ...